Aspira Women's Health Inc AWHL

Healthcare Biotechnology

Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.

OTCQB:AWHL - Post by User

Aspira Women's Health Inc

Bullboard Posts

(4)
•••

Post by AviseAnalyticson Feb 02, 2024 8:02am

100 Views

Post# 35858930

ASPIRA WOMEN’S HEALTH: IMPROVING OVARIAN CANCER DETECTION

$AWH

Excited to share an article about Aspira Women’s Health Inc (Nasdaq: AWH), a bio-analytical-based women's health company focused on developing gynecologic disease diagnostic tools.

Aspira's total revenue was $8.2 million for FY22, an increase of 20% compared to $6.8 million for FY21. Gross profit margin was 53% for FY22 compared to 45% for FY21.

The Company has a $1B pipeline opportunity for blood tests in ovarian cancer and endometriosis, and the Company is likely to see increased revenue growth due to its one-of-a-kind predictive tests. This makes Aspira an interesting watch.

Read on to know more:

https://www.aviseanalytics.com/aspiras-womens-health-improving-ovarian-cancer-detection/

Bullboard Posts

New Analyst Report Lifts Almonty Target Price to CDN$5.50